| Abstract: |
Plain Language Summary: What is this summary about? This is a summary of the results of a recent study. Researchers studied people with ALK-positive advanced non-small cell lung cancer (NSCLC) who were treated with medicines called ALK inhibitors. In the study, researchers looked at the order (or sequence) these medicines were given to people in the real world (not part of a clinical study), and how long the people took each medicine when they were given it as a first or second treatment. Several different ALK inhibitors are approved to treat this type of cancer. Understanding how well diffeent treatment sequences work will help healthcare professionals select the right treatments for their patients. What did this study find? This study used de-identified medical information from 273 patients in the Flatiron database (a collection of information about patients with cancer). This study found that in people who stopped their first ALK inhibitor treatment, about 1 out of 5 (22%) died without receiving a second treatment, and at least half of these people died within 4.0 months of stopping the first treatment. At least half of the people stopped taking their first treatment after 21.9 months and their second treatment after 7.3 months. At least half of the people stopped taking their first and second treatments after 29.4 months. When ALK inhibitors were taken in any sequence during treatment, at least half of the people stopped taking ALK inhibitors after 28.0 months. What do the findings of this study mean? The findings from this study show that not all people who stop taking their first treatment are able to take a second treatment. People take their first treatment for a longer time than their second treatment, highlighting the importance of selecting an effective first treatment option. This is an abstract of the Plain Language Summary of Publication article. View the full Plain Language Summary PDF of this article to read the full-text. © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
